NEW YORK, NY / ACCESSWIRE / September 12, 2017 / Marinus Pharmaceuticals and Teva both got a big boost in trading price yesterday for different reasons. Teva has finally found a new CEO and announced the sale of Paragard for $1.1 billion. Marinus released positive results from a mid-stage study of its ganaxolone in patients with CDKL5 disorder.

RDI Initiates Coverage on:

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) - http://www.rdinvesting.com/report/?ticker=TEVA

Marinus Pharmaceuticals Inc. (NASDAQ: MRNS) - http://www.rdinvesting.com/report/?ticker=MRNS

Teva Pharmaceutical's (NYSE: TEVA) shares saw big gains on Monday after the company finally announced a new CEO after a lengthy search and that it would be selling its contraceptive brand, Paragard, to a Cooper Cos unit for $1.1 billion. The stock closed up 19.35% with nearly 100 million shares traded. Former Lundbeck CEO, Kare Schultz, will be the company's new CEO, according to Bloomberg. Schultz will be replacing interim CEO, Yitzhak Peterburg, who has led the company since February after former CEO, Erez Vigodman, left the company. Regarding the Paragard sale, Wells Fargo Securities analyst, David Moris, said in a note, "Investors will like this news, as, in addition to a good price for the asset, and the recent share decline has been likely due in part to investor worries that the debt burden is high."

Access RDI's Teva Pharmaceutical Industries Ltd. Research Report at: http://www.rdinvesting.com/report/?ticker=TEVA

Marinus Pharmaceuticals' (NASDAQ: MRNS) shares blew up yesterday and closed the day up 33.01%. The stock even hit a new 52-week high of $5.44 during intra-day trading on colossal trading volume compared to usual. The big gains came after the company announced top-line results from its mid-stage study in patients with CDKL5 disorder, a severe and rare genetic epilepsy. Traders were excited to learn that the company's ganaxolone demonstrated a sizable and durable seizure-frequency reduction in the majority of patients. Some patients even experienced an increase in the number of days they did not have seizures.

Orrin Devinsky, M.D., director of the NYU Langone Medical Center's Comprehensive Epilepsy Center and principal investigator in the current study, stated, "I am impressed with the magnitude of seizure reduction and gain in seizure-free days seen with ganaxolone treatment in children with this highly refractory epilepsy. The durable anti-epileptic effect seen in several children distinguishes ganaxolone's efficacy from the more than 20 currently available anti-epileptic drugs that provide limited seizure control lasting a few weeks to months. When treating children with the severest forms of epilepsy such as CDKL5 disorder, there is a desperate need for new drugs that are well-tolerated, efficacious and easy to administer with no need for special monitoring. With no other treatment showing this degree of promise, I am excited to lead the effort to advance ganaxolone into potentially the first, late-stage clinical trial in children with CDKL5 disorder."

Access RDI's Marinus Pharmaceuticals Inc. Research Report at: http://www.rdinvesting.com/report/?ticker=MRNS

Our Actionable Research on Teva Pharmaceutical Industries Limited (NYSE: TEVA) and Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting